After a failed bid for Perrigo, Mylan has moved forward with a $9.9bn deal to merge with Swedish pharma company Meda, boosting its range of branded and generic pharmaceuticals. The deal also gives Mylan a better position in the market for over-the-counter (OTC) medicines. After the deal goes through, the Mylan/Meda OTC business will have sales of around $1bn per year. OTC medicines have become an attractive area of the pharma industry as their growth has outstripped the prescription drug sect...